Evidence map›Paper›PMID 36443438›Full record

ArticleProstate cancer and prostatic diseases2023

Retzius-sparing vs. standard robot-assisted radical prostatectomy for clinically localised prostate cancer: a comparative study.

Vincenzo Ficarra, Marta Rossanese, Manuel Gilante, Mauro Foti, Luciano Macchione, Giuseppe Mucciardi, Maurizio Martini, Gianluca Giannarini

Abstract read
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 4 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 4 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. [Mid- to Long-Term Urinary Continence Outcomes of Pelvic-Peritoneal Structure-Sparing Techniquein Robot-Assisted Radical Prostatectomy].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Vincenzo FicarraGaetano Barresi Department of Human and Paediatric Pathology, Urologic Section, University of Messina, Messina, Italy.
Marta RossaneseGaetano Barresi Department of Human and Paediatric Pathology, Urologic Section, University of Messina, Messina, Italy.
Manuel GilanteGaetano Barresi Department of Human and Paediatric Pathology, Urologic Section, University of Messina, Messina, Italy.
Mauro FotiGaetano Barresi Department of Human and Paediatric Pathology, Urologic Section, University of Messina, Messina, Italy.
Luciano MacchioneGaetano Barresi Department of Human and Paediatric Pathology, Urologic Section, University of Messina, Messina, Italy.
Giuseppe MucciardiGaetano Barresi Department of Human and Paediatric Pathology, Urologic Section, University of Messina, Messina, Italy.
Maurizio MartiniGaetano Barresi Department of Human and Paediatric Pathology, Pathology Section, University of Messina, Messina, Italy.
Gianluca GiannariniUrology Unit, Santa Maria della Misericordia University Hospital, Udine, Italy. gianluca.giannarini@hotmail.it.ORCID 0000-0002-6995-246X
University of Messina · ITOspedale Santa Maria della Misericordia di Udine · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRetzius-sparing robot-assisted radical prostatectomy (RARP) is not yet universally accepted due to still limited functional data and some concerns on oncological safety compared to the standard one. We assessed perioperative, pathological and early functional outcomes in patients with clinically localised prostate cancer treated with Retzius-sparing versus standard RARP.

methodsA single-surgeon cohort of 207 consecutive patients undergoing RARP was analysed. A later study group of 102 patients receiving the Retzius-sparing approach was compared with an earlier control group of 105 patients receiving the standard one. Urinary continence recovery 1 week after catheter removal was the primary study outcome. Urinary continence recovery 1, 2, 3 and 6 months after catheter removal, potency recovery 6 months postoperatively, rate of perioperative complications and positive surgical margins were secondary study outcomes.

resultsPatients in the study group reported significantly higher urinary continence recovery rates 1 week (91.2% vs. 54.3%, p < 0.001), 1 month (92.2% vs. 66.7%, p < 0.001), 2 months (95.1% vs. 74.3%, p < 0.001), 3 months (96.1% vs. 83.8%, p = 0.01), but not 6 months (97% vs 90.5%, p = 0.09) after catheter removal compared to controls. Potency recovery rates 6 months after catheter removal were significantly higher in the study than the control group (68.2% vs 51.6%, p = 0.03). On multivariable analyses, the Retzius-sparing approach was an independent predictor of 1-week urinary continence recovery, but not of 6-month potency recovery. There were significant differences neither in perioperative complication rate (9.8% in the study vs. 14.3% in the control group, p = 0.28) nor in positive surgical margin rate (9.8% in the study vs. 8.6% in the control group, p = 0.75).

conclusionsIn a comparative study, we observed a significant improvement in immediate urinary continence, but not in early potency recovery, using the Retzius-sparing compared to the standard approach for RARP, with no increase in perioperative complication and positive surgical margin rate.

Indexed as

Prostatic NeoplasmsRoboticsRobotic Surgical ProceduresHumansMaleMargins of ExcisionProstateProstatectomyTreatment Outcome

Identifiers

PMID36443438
OpenAlexW4310191270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.